{"entity":{"id":"fgl1","kind":"target","name":"FGL1","aka":["fibrinogen like 1","HFREP-1","hepassocin"],"tldr":"FGL1 is a liver protein that some tumours secrete; it binds LAG-3 on T cells and switches them off, separately from the MHC class II route. It explains part of how LAG-3 blockade works.","summary":"FGL1 (chromosome 8p22) is an immune-suppressive molecule that inhibits antigen-specific T-cell activation as a ligand of LAG-3, initiating signalling that inhibits the T-cell receptor in the immunological synapse; it binds LAG-3 independently of MHC class II, is liver-specific under normal conditions and is secreted by hepatocytes and certain tumour cells (UniProt Q08830, Q15116 context from P18627).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:3695","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3695"},{"label":"UniProt Q08830","url":"https://www.uniprot.org/uniprotkb/Q08830/entry"},{"label":"NCBI Gene 2267","url":"https://www.ncbi.nlm.nih.gov/gene/2267"}],"tags":["checkpoint-map"],"related":["lag3","hla-dra","relatlimab-nivolumab"],"cancers":[],"sections":[],"technologies":["lag3-blockade"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"FGL1","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:3695","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3695","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt Q08830","url":"https://www.uniprot.org/uniprotkb/Q08830/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:3695","ensembl":"ENSG00000104760","uniprot":"Q08830","entrez":"2267","biology":"A secreted fibrinogen-family protein; the second LAG-3 ligand after MHC class II.","whereFound":["Liver (UniProt Q08830)","Secreted by certain tumour cells (UniProt P18627)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/fgl1/","neighbours":{"target":[{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/"},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"drug":[{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/"}],"technology":[{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/"}],"pathway":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}